Public Health Experts Criticize Trump’s Executive Order on Childhood Vaccinations

Public health experts have expressed strong disapproval of President Donald Trump’s executive order regarding childhood vaccinations in the U.S. The order aims to separate combination vaccines such as the measles, mumps, and rubella (MMR) vaccine into individual shots. This change presents significant financial and logistical challenges for parents, healthcare providers, and pharmaceutical companies.

To implement these changes, drugmakers would need to reintroduce individual vaccines that have not been common in the U.S. for many years. Additionally, they would have to establish new manufacturing facilities to produce an increased number of vaccine doses. For parents, unbundling the MMR vaccine and spacing out appointments would result in more frequent trips to the doctor. This change could also burden pediatricians and increase costs related to medical supplies.

Research indicates that combination vaccines improve the likelihood of children being fully protected against infectious diseases before entering school. Dr. Anna Durbin from the Johns Hopkins Bloomberg School of Public Health stated, ‘We do things that are less convenient and more expensive if there’s a good reason to do it. There is no good justification for this. I think it’s very bad public health policy.’

Trump’s executive order directs federal officials to develop plans within 90 days to separate the MMR shot and space out other vaccines.

Pharmaceutical experts and former regulators suggest that implementing these changes could take years and cost millions of dollars. Currently, there are no individual vaccines in the U.S. for measles, mumps, or rubella; the FDA approves only combination shots for these viruses. The three-in-one method has been standard since the 1970s.

Dr. Jesse Goodman, a former FDA vaccine chief, mentioned that drug companies might need to conduct extensive studies to ensure the effectiveness of new individual shots. This would depend on how FDA regulators view the quality of data from original standalone vaccines. Presently, Merck, GSK, and other vaccine suppliers produce only the combination shot, as individual shots are typically used in lower-income countries that cannot afford the MMR vaccine.

Merck and GSK have defended their products’ safety and efficacy, stating that no scientific evidence supports separating the combination MMR vaccine into three individual shots.

The current MMR vaccine is administered in two doses: the first at age one and the second after age four. Splitting the shot into three components would increase the number of doctor visits to six. Separating other vaccines could further multiply these visits, which might lead to missed appointments and lower vaccination rates, according to Dr. Durbin.

President Trump has long held the view that American children receive too many vaccinations, advocating for smaller doses over extended periods. His executive order encourages giving parents more options for the timing and frequency of vaccinations. However, this would result in more individual shots than in other countries.

Despite the order’s significant implications, some experts doubt it will lead to substantial changes. The White House does not have the authority to compel drug companies to create new vaccines, and there is little business incentive to develop individual shots when combination vaccines are effective. Additionally, state governments, not the federal government, possess legal authority over vaccination requirements for schoolchildren. Dr. Paul Offit, a vaccine researcher, believes that states are unlikely to act on Trump’s advice.

The Associated Press Health and Science Department receives backing from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. However, the AP solely oversees all content.